

NOVARTIS AG  
Form 6-K  
March 27, 2007

## SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

Report on Form 6-K dated March 26, 2007

(Commission File No. 1-15024)

**Novartis AG**

(Name of Registrant)

Lichtstrasse 35

4056 Basel

Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F:  Form 40-F:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes:  No:

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes:  No:

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes:  No:



Novartis International AG  
Novartis Global Communications  
CH-4002 Basel  
Switzerland  
<http://www.novartis.com>

- Investor Relations Release -

**Tekturna®, first new type of high blood pressure medicine in a decade, provides additional blood pressure reduction when used with Diovan®**

- *New study results show more patients receiving both Tekturna and Diovan reached target blood pressure goal compared to those taking either agent alone(1)*
- *Tekturna approved in the US as first direct renin inhibitor, works by directly targeting an enzyme which triggers a process that can lead to high blood pressure*
- *Tekturna provides significant blood pressure reductions for a full 24 hours and generally well tolerated*
- *Urgent need for new therapies like Tekturna since nearly 70% of patients with high blood pressure still not achieving treatment goals(2)*

**Basel, March 26, 2007** Results from a new study have shown patients taking two Novartis cardiovascular medicines – the recently US-approved drug Tekturna® (aliskiren) and the leading therapy Diovan® (valsartan) – experienced greater reductions in blood pressure levels than those using either agent alone(1).

The study also found more patients receiving both Tekturna, which received US approval in March and represents the first type of new high blood pressure medicine in a decade, and Diovan reached their treatment goal compared to either drug alone(1).

Data from this trial involving 1,800 patients – the first large-scale study to assess the benefits of combining these medicines – were presented for the first time at the American College of Cardiology 56th Scientific Session in New Orleans.

Half of the patients in the eight-week trial taking both Tekturna and Diovan saw a reduction in blood pressure to the target of 140/90 mmHg (systolic/diastolic pressure), higher levels than seen in patients taking either of the medicines alone. Failure to properly control high blood pressure, also called hypertension, can increase the risk of heart attacks and strokes.

Tekturna and Diovan work in different ways to target the Renin Angiotensin System, one of the body's key regulators of blood pressure. Tekturna targets renin, an enzyme responsible for triggering a process that can lead to high blood pressure. Diovan, an angiotensin receptor blocker (ARB) and one of the world's most-prescribed cardiovascular medicines, blocks a hormone later in this system that causes narrowing of blood vessels(3).

These study results are exciting because they suggest the value of different mechanisms of action when Tekturna and Diovan are used together, said Suzanne Oparil, MD, Director of the Vascular Biology and Hypertension Program and Professor of Medicine at the University of Alabama at Birmingham in Alabama.

In addition to important blood pressure lowering, the combination of Tekturna and Diovan maintained a tolerability profile similar to that seen with either agent alone, Dr. Oparil said.

Tekturna received US regulatory approval for treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. In an extensive clinical trial program involving more than 6,400 patients, Tekturna provided significant blood pressure reductions for a full 24 hours. This once-daily oral therapy is expected to be available by the end of March in US pharmacies as 150 mg and 300 mg tablets.

A second study presented at the meeting compared Tekturna to ramipril, another high blood pressure medicine in a class known as ACE inhibitors. Results showed more patients treated with the Tekturna-based therapy reached their blood pressure goal than patients treated with the ramipril-based therapy (61.4% vs. 53.1% respectively)(4).

The need for new high blood pressure medicines is urgent given that this condition affects one in four adults globally and more than 70% of these patients remain uncontrolled(5). In fact, many require two or more medications to reach their target blood pressure goal(2,6). Uncontrolled high blood pressure can increase the risk of cardiovascular disease, the world's leading cause of death(6,7).

We are very encouraged by these results since they show Tekturna and Diovan are effective when used together, said James Shannon, MD, Global Head of Development at Novartis Pharma AG. Through our portfolio of high blood pressure medications, Novartis is committed to providing physicians with a wide range of tools to help patients lower their blood pressure.

#### **About Tekturna**

Tekturna received approval in March 2007 from the US Food and Drug Administration (FDA) for the treatment of high blood pressure as monotherapy or in combination with other high blood pressure medications. The use of Tekturna with maximal doses of ACE inhibitors has not been adequately studied. In September 2006, Tekturna known as Rasilez® outside the US was submitted to the European Medicines Agency (EMA) for review in the European Union. In clinical trials, the approved doses of Tekturna were generally well tolerated. Tekturna was developed in collaboration with Speedel.

#### **About Diovan**

Novartis remains at the forefront of cardiovascular medicine through development of innovative products like Diovan, the most-prescribed member of the ARB class (angiotensin receptor blocker) in the world today. Diovan is available for the treatment of high blood pressure in more than 100 countries, for the treatment of heart attack survivors in more than 70 countries and in more than 90 countries for the treatment of people with heart failure.

## Disclaimer

The foregoing release contains forward-looking statements which can be identified by the use of terminology such as "provides", "can", "effective", "is expected", or similar expressions, or by express or implied discussions regarding potential future regulatory filings, approvals or future sales of Tekturna/Rasilez, or potential future sales of Diovan. Such statements reflect the current views of the Novartis group of companies with respect to future events and are subject to certain risks, uncertainties and assumptions. There can be no guarantee that Tekturna/Rasilez will be approved for sale in any other market, or that Tekturna/Rasilez or Diovan will reach any particular sales levels. In particular, management's expectations regarding the approval and commercialization of Tekturna/Rasilez or Diovan could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data and new clinical data; unexpected regulatory actions or delays or government regulation generally; the company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; increased government, industry, and general public pricing pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

## References

1. Oparil S, Yarows S, Patel S, et al. The Direct Renin Inhibitor Aliskiren in Combination With the Angiotensin Receptor Blocker Valsartan Provides Additional Blood Pressure-Lowering Effects Compared With Either Agent Alone in Patients With Hypertension. Poster presented at American College of Cardiology 56th Annual Scientific Session, March 2007.
2. Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. *Hypertension*. 2007; 49:69-75.
3. Diovan Website. [http://www.diovan.com/info/about/about\\_diovan.jsp](http://www.diovan.com/info/about/about_diovan.jsp). Accessed November 28, 2006.
4. Andersen K, Weinberger M, Egan B, et al. Aliskiren-Based Therapy Lowers Blood Pressure More Effectively Than Ramipril-Based Therapy in Patients With Hypertension: A 6-Month, Randomized, Double Blind Trial. Poster presented at American College of Cardiology 56th Annual Scientific Session, March 2007.
5. Rosamond W, Flegal K, Friday G, et al. for the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics 2007 update. A report from the American Heart Association Statistics Committee and Stroke Subcommittee. *Circulation*. 2007;115.
6. Chobanian AV, Bakris GL, Black HR, et al. and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. *Hypertension*. 2003; 42:1206-1252.
7. World Health Organization. Main causes of death and global burden of disease (DALYs), world, all ages, projections for 2005. Available at: <http://www.who.int/whosis/highlight05.png>

###

**Novartis Media Relations**

**Richard Booton**

Novartis Pharma Communications

+41 61 324 4356 (direct)

+41 79 753 2593 (mobile)

richard.booton@novartis.com

**Corinne Hoff**

Novartis Global Media Relations

+41 61 324 9577 (direct)

+41 79 248 5717 (mobile)

corinne.hoff@novartis.com

e-mail: media.relations@novartis.com

**Novartis Investor Relations**

**International:**

<b>Ruth Metzler-Arnold</b>	+41 61 324 7944
Katharina Ambühl	+41 61 324 5316
Nafida Bendali	+41 61 324 3514
Jason Hannon	+41 61 324 2152
Thomas Hungerbuehler	+41 61 324 8425
Richard Jarvis	+41 61 324 4353

**North America:**

<b>Ronen Tamir</b>	+1 212 830 2433
Arun Nadiga	+1 212 830 2444
Jill Pozarek	+1 212 830 2445
Edwin Valeriano	+1 212 830 2456

e-mail: investor.relations@novartis.com

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Novartis AG**

Date: March 26, 2007

By: /s/ Malcolm B. Cheetham

Name: Malcolm B. Cheetham  
Title: Head Group Financial  
Reporting and Accounting